#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Non-small cell lung cancer metastatic Asthma Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Thrombotic thrombocytopenic purpura HER2 gene amplification Blood iron increased Immune thrombocytopenia Epilepsy Systemic candida Basal cell naevus syndrome Uveitis Haemolytic uraemic syndrome Medullary thyroid cancer Parkinson's disease Phenylketonuria NTRK gene fusion overexpression Encephalitis autoimmune PIK3CA related overgrowth spectrum More trials…

    Learn about Rare Diseases

    Haemophagocytic lymphohistiocytosis – Life with Disease Crigler-Najjar syndrome – Diagnostics CADASIL – Trials in Disease Pulmonary fibrosis – Basic Information Cerebral arteriovenous malformation haemorrhagic Andersen-Tawil syndrome – Basic Information Mantle cell lymphoma stage IV – Treatment Acquired haemophilia – Trials in Disease Hypereosinophilic syndrome – Basic Information Small intestine leiomyosarcoma More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Betula Alba Pollen Extract Lovotibeglogene Autotemcel Hexaminolevulinate Ramipril Erlotinib PRILOCAINE HYDROCHLORIDE GOLD SODIUM THIOSULFATE Cemiplimab Belumosudil Mesilate Cldn6 Car-T Cx-037231 Afatinib Eftrenonacog Alfa Omp12 ANERATRIGINE MESILATE Indacaterol Maleate Anthoxanthum Odoratum Lecanemab Lepidoglyphus Destructor Oditrasertib More therapies…

    Learn about Your Condition

    Breast angiosarcoma Endocarditis enterococcal Netherton's syndrome Post procedural hypotension Femoral neck fracture Chordoma Hairy cell leukaemia recurrent Cardiac disorder Spina bifida Short-bowel syndrome Congenital ureteric anomaly Neuromyopathy Suicidal ideation Mantle cell lymphoma recurrent Seasonal allergy More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Psoriasis

  • Study of TAK-279 and apremilast for adults with moderate to severe plaque psoriasis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Zasocitinib
    • Apremilast
    Germany Italy Poland

  • Study of zasocitinib (TAK-279) and apremilast compared to placebo in adults with moderate to severe plaque psoriasis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Zasocitinib
    • Apremilast
    Bulgaria Czechia France Germany Greece Hungary +3

  • Study on the Effects and Safety of Piclidenoson for Patients with Moderate-to-Severe Plaque Psoriasis

    Not recruiting

    3 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • PICLIDENOSON
    Bulgaria Greece Poland

  • Study on How Bimekizumab Affects People with Moderate to Severe Plaque Psoriasis and Psoriatic Arthritis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Psoriasis
    • Psoriatic arthropathy
    Investigated Drugs:
    • Bimekizumab
    Germany Poland

  • Study on the Effectiveness and Safety of Tildrakizumab for Patients with Moderate to Severe Genital Psoriasis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Tildrakizumab
    Bulgaria Hungary Poland

  • Study on the Effectiveness and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab for Patients with Moderate to Severe Plaque Psoriasis

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Jnj-77242113
    • Ustekinumab
    Austria Belgium Denmark Germany Hungary Poland +2
Previous Page
1 2 3 4 5 6 … 9
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!